Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$27,081 | -$12,295 | $46,885 | $13,437 |
| Dep. & Amort. | $2,732 | $2,125 | $2,048 | $2,061 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $4,364 | $4,894 | $5,298 | $4,469 |
| Change in WC | $2,420 | -$28,707 | -$98,635 | $109,651 |
| Other Non-Cash | $117,993 | -$737 | -$1,088 | -$696 |
| Operating Cash Flow | $100,428 | -$34,720 | -$45,492 | $128,922 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$651 | -$1,695 | -$1,587 | -$183 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | -$19,033 | -$138,014 | -$67,961 |
| Inv. Sales/Matur. | $0 | $46,052 | $39,372 | $37,248 |
| Other Inv. Act. | $38,789 | $0 | $0 | $0 |
| Investing Cash Flow | $38,138 | $25,324 | -$100,229 | -$30,896 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $0 | $365 | $14 | -$47,001 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $348 | $0 | $0 | $47,609 |
| Financing Cash Flow | $348 | $365 | $14 | $608 |
| Forex Effect | $0 | $0 | -$17 | $0 |
| Net Chg. in Cash | $138,914 | -$9,031 | -$145,724 | $98,634 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $74,379 | $83,410 | $224,254 | $130,483 |
| End Cash | $213,293 | $74,379 | $78,530 | $229,117 |
| Free Cash Flow | $99,777 | -$36,415 | -$47,079 | $128,739 |